(Press-News.org) Rockville, MD. (September 30, 2024) – The 2024 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by the National Foundation for Cancer Research (NFCR) and AIM-HI Accelerator Fund, will be held on October 18th at the National Press Club in Washington, DC.
This is the one event each year where key leaders from the entire cancer research and patient care ecosystem come together under one roof to share critical discoveries and ideas from all areas of cancer research, drug development, and patient care. This is where many innovative ideas and collaborations are born, and actionable plans and visions for the future fight against cancer are strategized. Collaboration between prominent researchers, global business leaders, entrepreneurs, and patient care advocates at every level working to cure cancer is the predominant theme of the Global Summit.
Once again, NFCR has developed another superb, high-quality oncology program this year that is second to none. The Global Summit features multifaceted sessions that transition from scientific discoveries to discussions on entrepreneurship and leadership, insights from investors, patient advocacy, and celebrations of extraordinary iconic leaders. The 2024 event promises to be an enriching experience for attendees.
Co-founded in 1973 by Nobel Prize recipient Albert Szent-Györgyi, M.D., Ph.D., and entrepreneur Franklin Salisbury, Sr., JD, NFCR provides scientists in the lab with the critical seed funding they need to make breakthrough discoveries and ultimately cures for cancer, with an emphasis on long-term transformative research often overlooked by other major funding sources. The Global Summit is NFCR’s hallmark annual event where we bring together the world’s top cancer experts, business leaders, entrepreneurs, and patient advocates to celebrate progress, share their vision, and chart new pathways in the quest for a cure.
“Our Global Summit fosters critical collaborations between the world’s top cancer
scientists, clinicians, biotech leaders, and entrepreneurs that not only accelerate research breakthroughs but speed the advancement of significant laboratory discoveries to reach patients’ bedsides,” said Dr. Sujuan Ba, Ph.D., President and CEO of NFCR. “The crucial basic discoveries generated in the laboratories over the past 51 years have transformed our understanding of cancer and revolutionized the way we approach treating, but these breakthrough discoveries need a collaborative approach and continued support to get through the pre-clinical stages needed to get to the patient’s bedside. This event fosters the dialogues to drive these potential cures forward.”
Now in its fourth year, NFCR’s highly packaged daylong 2024 Global Summit will begin with an opening keynote delivered by the highly respected scientist-entrepreneur, Drew Pardoll, MD., Ph.D., Director, Bloomberg- Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, followed by interactive and integrated panel discussions from key opinion leaders in cancer research.
Global Summit sessions are focused on unmet needs of current treatments, future innovative areas of therapies on the horizon, new and emerging developments, trends, early detection, and cancer prevention.
To kickoff afternoon programming, partnering with AIM-HI Accelerator Fund, we will host a Luncheon Award Ceremony for Women’s Leadership & Entrepreneurship, where Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), will be honored with the prestigious 3rd annual Beacon Award for Women Leaders in Oncology award.
Following the Beacon Award Ceremony, prize recipients of the 2024 AIM-HI Women’s Venture Competition, a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology start-ups, will also be honored during a luncheon award ceremony. This year’s winners include: First Prize with Distinction Nabanita Nawar, Ph.D., Co-Founder & CEO, HDAX Therapeutics, and Second Prize; Paraskevi Giannakakou, Ph.D., Co-Founder & CSO, ARMA Bio.
During the midday portion of the event, attendees will enjoy a different aspect of the programming element, The Innovative Oncology Companies Showcase and the Investors Perspective for Funding Early Stage Biotech. During this part of the event, several emerging and innovative oncology startups will showcase their technologies that are addressing unmet needs of current patient care. And several investors will share their feedback and perspectives with a fireside chat and dialogue with attendees.
The evening session presents highly anticipated programming that will begin with a keynote presentation by the globally-known author, cancer researcher and entrepreneur, and 2011 Pulitzer Prize Winner, Siddhartha Mukherjee, M.D., Associate Professor of Medicine, Columbia University Irving Medical Center, Columbia University.
During Dinner and Award Ceremony portion of the evening the 2024 Szent-Györgyi Prize winner, Dennis J. Slamon, M.D., Ph. D., from UCLA Health, Dinner and Award Ceremony, will be honored for his groundbreaking research discoveries that helped to shape the field of precision medicine for breast cancer patients.
To conclude the evening program, award-winning journalist, cancer survivor, and host of WUSA-9’s Great Day Washington, Kristen Berset-Harris, will moderate a star-studded panel “Live from the Press Club” to discuss the major weakness in current cancer research and care system that we must address and the future vision of how every part of the ecosystem working to cure cancer must join forces to collaborate in an integrated way to benefit patients as our ultimate goal.
Participants of the evening panel include: Dennis Slamon, M.D., Ph.D.; Margaret Foti, Ph.D., M.D.; Siddhartha Mukherjee, M.D.; Olufunmilayo Olopade, M.D.; Mohit Manrao, MBA; and Cancer Research Advocates: Shereen and Isabella Pavlides.
Dr. Raza Azra, a prominent physician-scientist who attended the 2023 Global Summit for the first time, stated: “Let me state right at the beginning that if I don’t attend another great conference for five years, I will not mind it because I was just given the opportunity to attend this one by NFCR. It was a humbling experience to be in the company of so many outstanding and accomplished scientists. Congratulations on organizing a totally mind-blowing Global Summit where NFCR assembles a constellation of shining stars under one roof for several days! Besides the talks and panel discussions, the opportunity to network and exchange ideas with others was deeply appreciated. I also loved the way you mixed hard science, heartbreaking oncology stories, and glamorous dinners. It was such a memorable event!”
Space is limited (by design), so reserve your tickets quickly for the 2024 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship on Friday, October 18th, 2024, at The National Press Club in Washington, D.C. All net proceeds from this event, which is open to the public, will support NFCR’s leading-edge cancer research programs.
Inquiries regarding sponsorship of this event can be made by e-mail at Sponsorship@nfcr.org or by phone at 1-800-321-CURE (2873). Ask to speak with Brian Wachtel, Executive Director of NFCR.
OncoDaily serves as NFCR’s media partner for the 2024 Global Summit. Press and media are encouraged to attend. Interested media should contact Jonathan Larsen, NFCR Chief Marketing Officer, at jlarsen@nfcr.org to make arrangements for attendance.
-------------------
About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 50+ years, NFCR has provided more than $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.
To learn more about the National Foundation for Cancer Research, visit NFCR.org.
About the AIM-HI Accelerator Fund
The AIM-HI Accelerator Fund (AIM-HI) is a 501(c)(3) nonprofit organization established in 2019 with an initial capacity-building grant from the National Foundation for Cancer Research to accelerate the translation of cancer drug discoveries by investing in seed-stage oncology companies. AIM-HI Accelerator Fund bridges the gap between innovative cancer discoveries and high-impact cancer treatments and technologies and facilitates an ecosystem for early-stage companies and entrepreneurs.
To learn more about the AIM-HI Accelerator Fund, visit AIM-HIAccelerator.org.
About the Szent-Györgyi Prize for Progress in Cancer Research
The Szent-Györgyi Prize for Progress in Cancer Research was established in 2006 by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Györgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine. The award recognizes outstanding scientists whose seminal discovery or pioneering body of work has contributed to cancer prevention, diagnosis, or treatment and has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.
About Beacon Award for Women Leaders in Oncology
Established in 2022 by the AIM-HI Accelerator Fund, a translational research and impact-investment partner of the National Foundation for Cancer Research (NFCR), the Beacon Award recognizes outstanding women leaders in the health and life sciences industry who have made a significant impact on advancing and advocating cancer treatment, detection, and diagnosis for patients around the world.
END
The world’s top cancer experts, entrepreneurs, and advocates to join the National Foundation for Cancer Research on October 18th, 2024, in Washington, DC, at the National Press Club
2024-09-30
ELSE PRESS RELEASES FROM THIS DATE:
Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction
2024-09-30
About The Study: In an open-label trial in patients with heart failure with preserved ejection fraction with left ventricular ejection fraction of 60% or greater, mavacamten, a cardiac myosin inhibitor, was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in left ventricular ejection fraction observed.
Corresponding Authors: To contact the corresponding authors, email Sanjiv J. Shah, MD, (sanjiv.shah@northwestern.edu) and Scott ...
Amy Vandiver, MD, PhD, of UCLA receives the 2024 Sagol Network GerOmic Award for Junior Faculty
2024-09-30
NEW YORK — The American Federation for Aging Research (AFAR) is pleased to announce the recipient of the 2024 Sagol Network GerOmic Award for Junior Faculty: Amy Vandiver, MD, PhD, Clinical Instructor Clinician-Investigator Track, University of California Los Angeles. Established in 2020, the Sagol Network GerOmic Award for Junior Faculty is a one- to two-year award given to junior faculty (MDs and PhDs) to conduct aging-related Omics (GerOmics) research.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, ...
Post-mastectomy radiation therapy can be shortened by nearly half for patients planning breast reconstruction
2024-09-30
WASHINGTON, September 30, 2024 — An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
While radiation therapy following mastectomy to remove breast cancer is known to improve survival rates for certain patients who are at higher risk of recurrence, RT CHARM is the first multi-institutional international study to show that a shorter course ...
IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer
2024-09-30
WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
“We tested two contemporary, advanced forms of external ...
Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer
2024-09-30
WASHINGTON, September 30, 2024 — People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival. Findings of the multi-institutional phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
The ...
Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer
2024-09-30
WASHINGTON, September 30, 2024 — Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%. De-intensified treatments involving a lower radiation dose and immunotherapy in place of chemotherapy did not perform as well as the more rigorous chemoradiation approach. Findings of the NRG Oncology HN005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual ...
CAR-T safe and effective on an outpatient basis in community hospitals
2024-09-30
(WASHINGTON – September 30, 2024) In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances.
LBCL is a cancer affecting B lymphocytes, a type of white blood cell. It can progress rapidly and is fatal if untreated, although most forms of LBCL respond well to standard ...
City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting
2024-09-30
LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, is part of today’s press conference program at the American Society for Radiation Oncology (ASTRO) Annual Meeting, where a renowned City of Hope radiation oncologist will present phase 3 clinical trial data showing that people with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time. The results suggest that the timing of when immunotherapy is given plays a key role in its ...
A new and unique fusion reactor comes together with PPPL's contributions
2024-09-30
Like atoms coming together to release their power, fusion researchers worldwide are joining forces to solve the world’s energy crisis. Harnessing the power of fusing plasma as a reliable energy source for the power grid is no easy task, requiring global contributions.
The Princeton Plasma Physics Laboratory (PPPL) — a U.S. national laboratory funded by the Department of Energy (DOE) — is leading several efforts on this front, including collaborating on the design and development of a new fusion device at the University of Seville in Spain. The SMall Aspect Ratio Tokamak (SMART) strongly ...
Reduced risk of serious cardiovascular disease after COVID vaccination
2024-09-30
People who have been fully vaccinated against COVID-19 have a significantly lower risk of developing more severe cardiovascular conditions linked to COVID-19 infection, according to a nationwide study at the University of Gothenburg. At the same time, some cardiovascular effects are seen after individual doses of the vaccine.
The COVID-19 vaccine aims to reduce complications and overall mortality from the disease. At the same time, some cardiovascular effects have been seen after individual doses of the vaccine. A rare acute side effect is inflammation of the cardiac muscle or the pericardium in young men following mRNA vaccination. In terms of other cardiovascular ...